NCT00494117

Completed

Investigation of Heart Failure Status Over Time Using Respir...

ResMed Source

Other study identifiers

Sponsor study identifier

X07- 0052

Study Type

observational

Actual enrollment (reported)

50

Locations

1 country

Sites

1

Timeline

Study Start

June 2007

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

March 2010

Actual (reported)

Study Completion

March 2010

Actual (reported)

Brief Summary

The purpose of the study is to investigate respiratory indicators for clinically important changes in Heart Failure status over time.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 50 participants
Study completion date: March 2010
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
June 2007
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
June 28, 2007
Actual (reported)
First Posted
June 29, 2007
Actual (reported)
Primary Completion
March 2010
Actual (reported)
Study Completion
March 2010
Actual (reported)

Last Updated: July 27, 2010
Status Verified: July 2010
Last Update Submitted: July 25, 2010

Conditions

Heart Failure, Congestive Sleep Apnea Syndromes

Interventions

ApneaLinkDevice

A two channel sleep screening device for the assessment of Sleep Disordered Breathing.

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

The population under investigation is moderate to severe heart failure who are outpatients of a major Sydney hospital.

You may qualify if:

Moderate to severe Heart Failure (as determined by Echocardiogram or by treating physician)

You may not qualify if:

Sponsors & Collaborators

ResMed
Industrylead

Study Sites (1)

Royal Prince Alfred Hospital

Camperdown, New South Wales, 2050, Australia

MeSH Terms

Conditions

Heart FailureSleep Apnea Syndromes

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesApneaRespiration DisordersRespiratory Tract DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System Diseases

Study Officials

Rachel A Coxon, BE/MBiomedE
ResMed/The University of New South Wales
STUDY DIRECTOR
Klaus Schindhelm, PhD
ResMed/The University of New South Wales
STUDY DIRECTOR
Jodie Lattimore, PhD
Royal Prince Alfred Hospital, Sydney, Australia
STUDY DIRECTOR
Ian Wilcox, PhD
Royal Prince Alfred Hospital/The University of Sydney
PRINCIPAL INVESTIGATOR

Enrollment

50 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: INDUSTRY

Study Record Dates

First Submitted

June 28, 2007

First Posted

June 29, 2007

Study Start

June 2007

Date type not reported

This date has not been verified as actual or estimated.

NCT00495196

Cardiovascular Responses in Congestive Heart Failure With Cheyne- Stokes Respiration

Not ApplicableCompleted

NCT01657188

Effects of Adaptive Servoventilation in Patients With Systolic Heart Failure and Sleep-Disordered Breathing

Completed

NCT00355511

Heart Failure Evaluation Acute Referral Team Trial (HEARTT)

Not ApplicableWithdrawn

NCT00383630

Bone Marrow Cell Transplantation to Improve Heart Function in Individuals With End-Stage Heart Failure

Phase 2Terminated

NCT00791674

Opiate Sleep Disordered Breathing Study

Unknown

NCT00415545

Educational Program to Improve Heart Failure Outcomes in Adults Living in Rural Areas

Phase 3Completed

Malignant disease affecting gas exchange or respiratory parameters
Medications compromising breathing with no adverse affects on heart failure
Clinically significant (moderate to severe) asthma requiring therapy
Chronic parenchymal lung disease (FEV1/FVC ratio = 65% or as determined by the treating physician)
Severe pulmonary hypertension
Heart failure due to alcohol abuse or chemotherapy
Narcotic abuse/intravenous drug use (including HIV+ and hepatitis C)
Alcohol consumption \> 80g/day
Patients receiving home Oxygen
Methicillin- resistant Staphylococcus aureus infection
Narcolepsy
Cataplexy
Enrolled in any concurrent study, that may confound the results of this study.
Inability or refusal to sign the Patient Consent Form
Inability or refusal to adhere to protocol requirements

Contact the study team to confirm eligibility.

Primary Completion

March 2010

Actual (reported)

Study Completion

March 2010

Actual (reported)

Last Updated

July 27, 2010

Record last verified: 2010-07

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00494117
Data provider: ClinicalTrials.gov
Source updated: 2010-07-27
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:26:35 UTC

Locations

AU(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations